We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Morphotek Raises $40 Million to Advance Its Antibody Pipeline

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Morphotek Raises $40 Million to Advance Its Antibody Pipeline "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Morphotek® Inc. has announced the closing of a $40 million Series D financing. The financing was led by Investor Growth Capital of New York and included participation of new investors MDS Capital and Hunt BioVentures as well as existing investors Forward Ventures, Morgenthaler Ventures, SR One, Flagship Ventures, Burrill & Co., CB Health Ventures, and Rock Maple Ventures.

The funds will be used primarily to further clinical development of the Company's lead therapeutic antibodies, MORAb-003 and MORAb- 009, and to advance its pipeline of preclinical antibodies for the treatment of oncology, inflammatory and infectious diseases.

Morphotek's lead antibody, MORAb-003, specifically targets the folate receptor alpha, a cell surface receptor over-expressed on ovarian, breast, colorectal, lung and renal tumors.

Preclinical studies have demonstrated that the folate receptor alpha pathway is critical for both initiating and sustaining malignant characteristics of cancer cells over-expressing this protein.

The antibody is currently being evaluated in a multi-institutional Phase 2 clinical trial in patients with relapsed platinum-sensitive ovarian cancer.

To date, clinical results have shown that the antibody is well tolerated with no significant drug-related adverse events reported when administered either in mono or combination therapy.

Morphotek's second clinical-stage compound, MORAb-009, is currently in a Phase 1 study ongoing at Johns HopkinsFox Chase Cancer Center and the National Cancer Institute in patients with pancreatic, mesothelioma, non small cell lung and ovarian cancer.

"We are delighted to have completed this financing and welcome the new investors that bring additional biopharmaceutical expertise to the Company," said Nicholas C. Nicolaides, Ph.D., Morphotek's President and Chief Executive Officer.

"We have developed a broad portfolio of monoclonal antibodies, and the participation of the new and existing investors in this round underscores the potential of our therapeutic pipeline and underlying antibody technologies."

"These funds provide the Company with sufficient resources to support our product development strategy and goals around our lead therapeutic antibodies and our preclinical pipeline."

"Morphotek's robust product pipeline and unique antibody technologies address unmet needs in large markets and offer tremendous upside," said Sunny Sharma, M.D., Venture Partner of Investor Growth Capital.

"I am pleased to be joining the Board of Directors of Morphotek and look forward to contributing to the Company's success."

In addition to Dr. Sharma, Benjamin Rovinski, Ph.D., Venture Partner of MDS Capital, will be joining Morphotek's Board as part of the financing. Montgomery & Co. was the exclusive private placement agent for the financing.